基因治疗:昨天,今天和明天

Q4 Biochemistry, Genetics and Molecular Biology
Biochemist Pub Date : 2023-08-24 DOI:10.1042/bio_2023_137
Heather Doran
{"title":"基因治疗:昨天,今天和明天","authors":"Heather Doran","doi":"10.1042/bio_2023_137","DOIUrl":null,"url":null,"abstract":"This issue focuses on one of the most keenly anticipated and researched topics in medicine – gene therapy. With recent advancements in the field, the hope is that some of the most debilitating diseases, many that seriously affect children, can begin to be treated.It wouldn’t be right to cover this topic in The Biochemist without also acknowledging the ethical considerations of these treatments. First, there are decisions to be made on what conditions might be ‘fixed’ via these methods, if they need fixing at all and what is the outcome for those that undergo these treatments? Although it is heartening to see developments in the treatment of diseases that can have serious life-limiting effects, who gets to decide which ones are prioritized for research?The second factor, which is discussed in a number of articles in this issue, relates to the cost of gene therapy treatments. Research has taken many years and a single-point treatment needs to cover costs, but the extraordinary level of finance required for one of these treatments also limits who has access. How can we make sure all who need it can receive it? Currently, gene therapy treatments are the most expensive treatment method across all medicine, with a single treatment costing millions of dollars.Lastly, the question is what comes next now that this technology is in use? What limits could/should there be (or not be) on the use of gene therapy?Biology, medicine and research are never in isolation from society and this is one area that highlights how important it is to have engagement and involvement from patients and the public, along with law and experts in the social sciences in the discussions of the creation, limits and applications of these approaches.The possibilities of gene therapy took longer than expected to be realized. Now different delivery methods of viral and non-viral vectors have been created to make the process more efficient and safer. The articles in this issue are looking at in vivo gene therapies, the challenges for the future and the steps that have taken us to where we are today.","PeriodicalId":35334,"journal":{"name":"Biochemist","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Gene therapy: yesterday, today and tomorrow\",\"authors\":\"Heather Doran\",\"doi\":\"10.1042/bio_2023_137\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This issue focuses on one of the most keenly anticipated and researched topics in medicine – gene therapy. With recent advancements in the field, the hope is that some of the most debilitating diseases, many that seriously affect children, can begin to be treated.It wouldn’t be right to cover this topic in The Biochemist without also acknowledging the ethical considerations of these treatments. First, there are decisions to be made on what conditions might be ‘fixed’ via these methods, if they need fixing at all and what is the outcome for those that undergo these treatments? Although it is heartening to see developments in the treatment of diseases that can have serious life-limiting effects, who gets to decide which ones are prioritized for research?The second factor, which is discussed in a number of articles in this issue, relates to the cost of gene therapy treatments. Research has taken many years and a single-point treatment needs to cover costs, but the extraordinary level of finance required for one of these treatments also limits who has access. How can we make sure all who need it can receive it? Currently, gene therapy treatments are the most expensive treatment method across all medicine, with a single treatment costing millions of dollars.Lastly, the question is what comes next now that this technology is in use? What limits could/should there be (or not be) on the use of gene therapy?Biology, medicine and research are never in isolation from society and this is one area that highlights how important it is to have engagement and involvement from patients and the public, along with law and experts in the social sciences in the discussions of the creation, limits and applications of these approaches.The possibilities of gene therapy took longer than expected to be realized. Now different delivery methods of viral and non-viral vectors have been created to make the process more efficient and safer. The articles in this issue are looking at in vivo gene therapies, the challenges for the future and the steps that have taken us to where we are today.\",\"PeriodicalId\":35334,\"journal\":{\"name\":\"Biochemist\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biochemist\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1042/bio_2023_137\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemist","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1042/bio_2023_137","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

摘要

这期的重点是医学上最热切期待和研究的主题之一-基因治疗。随着该领域的最新进展,人们希望能够开始治疗一些最令人衰弱的疾病,其中许多严重影响儿童。如果不承认这些治疗的伦理考虑,在《生物化学家》中讨论这个话题是不对的。首先,需要决定哪些情况可以通过这些方法“修复”,如果它们需要修复,以及接受这些治疗的人的结果是什么?尽管在治疗可能严重限制生命的疾病方面取得进展令人振奋,但谁来决定哪些疾病应该优先进行研究呢?第二个因素与基因治疗的费用有关,这在本期的许多文章中都有讨论。研究已经进行了多年,单点治疗需要支付费用,但其中一种治疗所需的巨额资金也限制了谁能获得这种治疗。我们如何确保所有需要的人都能得到它?目前,基因疗法是所有药物中最昂贵的治疗方法,单次治疗就需要花费数百万美元。最后一个问题是,既然这项技术已经投入使用,接下来会发生什么?基因疗法的使用可能/应该(或不应该)有哪些限制?生物学、医学和研究从来都不是孤立于社会之外的,这一领域突出表明,让患者和公众以及法律和社会科学专家参与和参与讨论这些方法的创造、限制和应用是多么重要。基因治疗的可能性比预期的实现时间要长。现在,不同的病毒载体和非病毒载体的递送方法已经被创造出来,使这一过程更有效、更安全。本期的文章关注的是体内基因疗法,未来的挑战以及我们取得今天成就的步骤。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Gene therapy: yesterday, today and tomorrow
This issue focuses on one of the most keenly anticipated and researched topics in medicine – gene therapy. With recent advancements in the field, the hope is that some of the most debilitating diseases, many that seriously affect children, can begin to be treated.It wouldn’t be right to cover this topic in The Biochemist without also acknowledging the ethical considerations of these treatments. First, there are decisions to be made on what conditions might be ‘fixed’ via these methods, if they need fixing at all and what is the outcome for those that undergo these treatments? Although it is heartening to see developments in the treatment of diseases that can have serious life-limiting effects, who gets to decide which ones are prioritized for research?The second factor, which is discussed in a number of articles in this issue, relates to the cost of gene therapy treatments. Research has taken many years and a single-point treatment needs to cover costs, but the extraordinary level of finance required for one of these treatments also limits who has access. How can we make sure all who need it can receive it? Currently, gene therapy treatments are the most expensive treatment method across all medicine, with a single treatment costing millions of dollars.Lastly, the question is what comes next now that this technology is in use? What limits could/should there be (or not be) on the use of gene therapy?Biology, medicine and research are never in isolation from society and this is one area that highlights how important it is to have engagement and involvement from patients and the public, along with law and experts in the social sciences in the discussions of the creation, limits and applications of these approaches.The possibilities of gene therapy took longer than expected to be realized. Now different delivery methods of viral and non-viral vectors have been created to make the process more efficient and safer. The articles in this issue are looking at in vivo gene therapies, the challenges for the future and the steps that have taken us to where we are today.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Biochemist
Biochemist Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)
CiteScore
1.20
自引率
0.00%
发文量
41
期刊介绍: This lively and eclectic magazine for all life scientists appears six times a year. Its quirky style and astute selection of serious and humorous articles ensures that the magazine"s appeal is by no means restricted to that of the avid biochemist. Specially commissioned articles from leading scientists bring a popular science perspective direct to you! Forthcoming themes include: RNAi, Money in Science, Extremophiles, Biosystems and Mathematical Modelling, Renascence of Mitochondria, Prions & Protein factors, Imaging live cells and Model organisms.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信